TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23114372

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 101

Group type: COMPARATOR
Intervention: MenACWY-PS
Number of subjects: 101

Group type: COMPARATOR
Intervention: Vaccine-naive group
Number of subjects: 101
Study: 23114473

Group type: EXPERIMENTAL
Intervention: Preventive colorectal resections
Number of subjects: 105

Group type: COMPARATOR
Intervention: Screening endoscopy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Excision of desmoid tumors
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT) and radiotherapy (RT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Screening and treatment modalities
Number of subjects: 105

Group type: COMPARATOR
Intervention: Desmoid tumors
Number of subjects: 105
Study: 23115344

Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by neuropsychological testing)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Treatment adherence (assessed using the Heart Failure Compliance Questionnaire)
Number of subjects: 149
Study: 23115630

Group type: EXPERIMENTAL
Intervention: BCI-based attention training game system
Number of subjects: 20
Study: 23116179

Group type: EXPERIMENTAL
Intervention: Ectopic expression of B-function genes (PISTILLATA homologs) in C. parviflora
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard sepal-petal species C. arborescens
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: C. parviflora
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: In situ hybridization analysis of C. parviflora
Number of subjects: 2
Study: 23116538

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) - Privigen®, dose 0.4 gram/kg, for 6 months
Number of subjects: 9
Study: 23116553

Group type: EXPERIMENTAL
Intervention: AKR1C3 IVS4-212 GG genotype
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CBR3 G11A
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: ABCB1 G2677T/A
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: ABCB1 IVS26+59 T>G
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: AKR1C3 IVS4-212 C<G genotype
Number of subjects: 151
Study: 23116602

Group type: EXPERIMENTAL
Intervention: 1st, 2nd, 3rd line treatments for CML
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Accelerated phase (AP) and blast phase (BP) treatments
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: CML treatments
Number of subjects: 900
Study: 23117560

Group type: EXPERIMENTAL
Intervention: Bicycling to school
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no change in lifestyle)
Number of subjects: 43
Study: 23117571

Group type: EXPERIMENTAL
Intervention: Community-based epidemiology of viral respiratory infections (ARI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based epidemiology of gastrointestinal infections (AGE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control material from children without symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary analyses of specific respiratory and gastrointestinal pathogens
Number of subjects: 0
Study: 23117698

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects aged ≥45 years
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Aging HIV-infected patients (≥45 years)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Age, smoking, advanced symptomatic HIV infection
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Aging HIV-infected subjects (≥45 years)
Number of subjects: 803
Study: 23118111

Group type: EXPERIMENTAL
Intervention: Computer-assisted erosion segmentation volume measurement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: MRI measures (both methods)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Construct correlational validity of MRI methods
Number of subjects: 32

Group type: COMPARATOR
Intervention: DAS28
Number of subjects: 32
Study: 23118116

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg infusion at months 0 and 6 with 100 mg methylprednisolone
Number of subjects: 8
Study: 23118984

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine (1.5×10^8 pfu)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine
Number of subjects: 30
Study: 23119077

Group type: EXPERIMENTAL
Intervention: Knowledge of clinical preventive services recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of prioritization according to MoH guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendation rates by level of training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall knowledge of preventive services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritization of preventive services
Number of subjects: 0
Study: 23121323

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 1900
Study: 23122784

Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg, orally daily) plus capecitabine (2000 mg/m², orally from day 1 to day 14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 45
Study: 23124321

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered on days 1 and 15
Number of subjects: 19
Study: 23128051

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation for OCD
Number of subjects: 0
Study: 23128154

Group type: EXPERIMENTAL
Intervention: v1.0 smoking cessation quit success genotype score
Number of subjects: 0
Study: 23129135

Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV) in patients with type 2 diabetes
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV)
Number of subjects: 89
Study: 23129163

Group type: EXPERIMENTAL
Intervention: Patient Acuity Rating (PAR) score provided by the primary team
Number of subjects: 48

Group type: COMPARATOR
Intervention: Primary team's PAR score
Number of subjects: 48
Study: 23129758

Group type: EXPERIMENTAL
Intervention: Detection of acute HIV infection at enrollment
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Documentation of HIV seroconversion
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Detection of recent HIV infection using multiassay algorithm (MAA)
Number of subjects: 2067
Study: 23130114

Group type: EXPERIMENTAL
Intervention: Various interventions in RCTs of type 2 diabetes mellitus (specific interventions not detailed in the abstract)
Number of subjects: 91842

Group type: EXPERIMENTAL
Intervention: Selection for renal disease (defined by decline in renal function or presence of proteinuria)
Number of subjects: 91842

Group type: EXPERIMENTAL
Intervention: Prior cardiovascular morbidity
Number of subjects: 91842

Group type: EXPERIMENTAL
Intervention: Inclusion and exclusion criteria of RCTs
Number of subjects: 91842
Study: 23130118

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (Clopidogrel)
Number of subjects: 229
Study: 23130122

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 300

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 300
Study: 23130134

Group type: EXPERIMENTAL
Intervention: n3-PUFAs 2 g orally twice daily (minimum of 6 g)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: n3-PUFAs
Number of subjects: 260

Group type: COMPARATOR
Intervention: n3-PUFAs and Placebo
Number of subjects: 260
Study: 23130135

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d with high on-aspirin RPR and low von Willebrand factor
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d with high on-aspirin RPR and low platelet count
Number of subjects: 1001
Study: 23130154

Group type: EXPERIMENTAL
Intervention: Multidomain prevention program for stroke and dementia
Number of subjects: 3908

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 3908
Study: 23130162

Group type: EXPERIMENTAL
Intervention: End-diastolic IMT
Number of subjects: 5633

Group type: EXPERIMENTAL
Intervention: Peak-systolic IMT
Number of subjects: 5633

Group type: EXPERIMENTAL
Intervention: Change in carotid IMT during the cardiac cycle
Number of subjects: 5633

Group type: COMPARATOR
Intervention: Peak-systolic IMT reference values
Number of subjects: 5633
Study: 23130172

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23131206

Group type: EXPERIMENTAL
Intervention: 6 μg PhtD vaccine candidate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 25 μg PhtD vaccine candidate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 100 μg PhtD vaccine candidate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All dose levels of PhtD vaccine candidate
Number of subjects: 63
Study: 23131904

Group type: EXPERIMENTAL
Intervention: BRCA genetic testing
Number of subjects: 775
Study: 23134762

Group type: EXPERIMENTAL
Intervention: High-dose oral cholecalciferol (vitamin D3)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 23134813

Group type: EXPERIMENTAL
Intervention: Tracheal suctioning maneuver using a 16-French suction catheter with a suction pressure of -400 mbar.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tracheal suctioning maneuver
Number of subjects: 25
Study: 23135257

Group type: EXPERIMENTAL
Intervention: FA global model
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: FA selected model
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient model
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clinical classifiers model
Number of subjects: 57
Study: 23136057

Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD)
Number of subjects: 203
Study: 23136848

Group type: EXPERIMENTAL
Intervention: HLA-DQB1*0602 allele-positive individuals with OSAS
Number of subjects: 894

Group type: COMPARATOR
Intervention: HLA-DQB1*0602 allele-negative individuals with OSAS
Number of subjects: 894

Group type: COMPARATOR
Intervention: Individuals without OSAS
Number of subjects: 894
Study: 23136929

Group type: EXPERIMENTAL
Intervention: DAFNE delivered over five consecutive days (1 week course)
Number of subjects: 213

Group type: COMPARATOR
Intervention: DAFNE delivered one day a week over five weeks (5 week course)
Number of subjects: 213
Study: 23137499

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 1 × 10(5)/kg or 5 × 10(5)/kg CD34(+) cells
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: G-CSF-mediated stem cell mobilization
Number of subjects: 167
Study: 23137723

Group type: EXPERIMENTAL
Intervention: Inattention symptoms
Number of subjects: 401
Study: 23138190

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 40
Study: 23138404

Group type: EXPERIMENTAL
Intervention: Draft expectations survey (Phase 1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Draft expectations survey (Phase 2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Final expectations survey (Phase 3)
Number of subjects: 25
Study: 23138680

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 681
Study: 23138731

Group type: EXPERIMENTAL
Intervention: Drug-resistant virus
Number of subjects: 0
Study: 23139273

Group type: EXPERIMENTAL
Intervention: Contact lens sensor (CLS) monitoring during 24-hour IOP monitoring, two sessions 1 week apart.
Number of subjects: 40
Study: 23140536

Group type: EXPERIMENTAL
Intervention: Rapamycin (target plasma levels between 4 and 8 ng/ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 17
Study: 23140654

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 101
Study: 23141679

Group type: EXPERIMENTAL
Intervention: Mechanochemical endovenous ablation (MOCA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both MOCA and RFA
Number of subjects: 68
Study: 23142061

Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200 mg once daily for 7 days)
Number of subjects: 37
Study: 23142076

Group type: EXPERIMENTAL
Intervention: Primary surgery
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Interval surgery after NACT
Number of subjects: 55
Study: 23143411

Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR), 150-300 mg/day
Number of subjects: 23
Study: 23143773

Group type: EXPERIMENTAL
Intervention: FP85A alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: FP85A followed by MVA85A
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: FP85A and MVA85A
Number of subjects: 3
Study: 23143939

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac tromethamine 31.5 mg (15.75 mg per nostril)
Number of subjects: 30
Study: 23144193

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg by mouth once daily on days 1-28 of a 28-day cycle with rituximab administered weekly during cycle one and then on day one of subsequent cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Everolimus in combination with rituximab
Number of subjects: 26
Study: 23144200

Group type: EXPERIMENTAL
Intervention: Melphalan, lenalidomide, and dexamethasone; melphalan 5 mg/m²/day for 4 days, lenalidomide 10 mg/day for 21 days, dexamethasone 20-40 mg once a week every 28 days for 12 cycles.
Number of subjects: 16
Study: 23144326

Group type: EXPERIMENTAL
Intervention: Genome-wide significant single nucleotide polymorphisms (SNPs) affecting Clara cell secretory protein (CC16) levels
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Genome-wide significant single nucleotide polymorphisms (SNPs) affecting surfactant protein D (SP-D) levels
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Candidate SNPs associated with COPD susceptibility
Number of subjects: 1951
Study: 23145537

Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 220 mg per capsule, two capsules per day for three months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 37
Study: 23145922

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention by pharmacists and other healthcare professionals
Number of subjects: 477
Study: 23146246

Group type: EXPERIMENTAL
Intervention: SSR149415 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSR149415 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23146560

Group type: EXPERIMENTAL
Intervention: Cannabis withdrawal symptoms reported by participants (113 out of 120, 94.2%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Actions taken to relieve withdrawal symptoms (104 out of 120, 92.0%)
Number of subjects: 120
Study: 23146956

Group type: EXPERIMENTAL
Intervention: Lapatinib 1250mg/day and Sorafenib 400mg twice daily (RPTD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib combination treatment
Number of subjects: 30
Study: 23147218

Group type: EXPERIMENTAL
Intervention: ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ABT-751 with carboplatin
Number of subjects: 20
Study: 23148122

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23148516

Group type: EXPERIMENTAL
Intervention: Class-based HPV vaccination
Number of subjects: 134

Group type: COMPARATOR
Intervention: Age-based HPV vaccination
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Scaled-up class-based vaccination
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: HPV vaccine delivery excluding vaccine costs
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Financial scaled-up costs excluding vaccine and salaries
Number of subjects: 134
Study: 23148799

Group type: EXPERIMENTAL
Intervention: Sumatriptan auto-injector (6 mg subcutaneous)
Number of subjects: 63
Study: 23149277

Group type: EXPERIMENTAL
Intervention: HRQCT-based analysis of spinal bone density and microstructure, finite element analysis (FEA)
Number of subjects: 73
Study: 23150649

Group type: EXPERIMENTAL
Intervention: Smoking (55.5%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Physical inactivity (48.2%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Arterial hypertension (46.6%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Dyslipidemia (34.9%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Obesity (22.3%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption (33.0%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Short sleep duration (20.6%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Migraine (26.5%)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (74% in women aged 25 years or older)
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4467
Study: 23150682

Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TGs)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Increased free fatty acids (FFAs)
Number of subjects: 219
Study: 23150931

Group type: EXPERIMENTAL
Intervention: Self-reported adherence using written logs
Number of subjects: 135

Group type: COMPARATOR
Intervention: Electronic recording of device usage
Number of subjects: 135
Study: 23151076

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UCMSCs) therapy
Number of subjects: 16
Study: 23151237

Group type: EXPERIMENTAL
Intervention: Self-Administered Comorbidity Questionnaire (SCQ)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 525
Study: 23151373

Group type: EXPERIMENTAL
Intervention: Combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50 mg/kg on 3-7 days/week)
Number of subjects: 22
Study: 23151395

Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment programme (patient education, exercise, diet, insoles, paracetamol and/or NSAIDs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (two information leaflets on KOA and advice regarding non-surgical treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 23151831

Group type: EXPERIMENTAL
Intervention: CAD-assisted reading
Number of subjects: 618

Group type: COMPARATOR
Intervention: Unassisted reading
Number of subjects: 618
Study: 23152364

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug eluting stents (BP-DES)
Number of subjects: 5834

Group type: COMPARATOR
Intervention: Durable polymer drug eluting stents (DP-DES)
Number of subjects: 5834
Study: 23153506

Group type: EXPERIMENTAL
Intervention: Doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox) at doses of 5 mg/m(2), 10 mg/m(2), 20 mg/m(2), 30 mg/m(2), 40 mg/m(2), 50 mg/m(2), and 60 mg/m(2) intravenously infused once every 4 weeks for a maximum of six cycles
Number of subjects: 29
Study: 23154208

Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels in patients with kidney cancer
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels in patients with kidney cancer
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels after tumor excision
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels after tumor excision
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Correlation between urine AQP1 and PLIN2 levels and tumor size
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine AQP1 levels in patients with kidney cancer compared to common kidney diseases
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine PLIN2 levels in patients with kidney cancer compared to common kidney diseases
Number of subjects: 165

Group type: COMPARATOR
Intervention: Specificity of urine AQP1 and PLIN2 to identify kidney cancer
Number of subjects: 165
Study: 23154459

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Moderate/severe NPDR cases
Number of subjects: 29
Study: 23154470

Group type: EXPERIMENTAL
Intervention: F-FDG PET/CT
Number of subjects: 12
Study: 23155695

Group type: EXPERIMENTAL
Intervention: Peripubertal girls
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (overweight African-American women)
Number of subjects: 46
Study: 23157720

Group type: EXPERIMENTAL
Intervention: PEGylated interferon (PEG-IFN) α-2a or PEG-INF α-2b combined with daily ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 388
Study: 23157877

Group type: EXPERIMENTAL
Intervention: Constrained algorithm for PET/CT image registration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unconstrained algorithm for PET/CT image registration
Number of subjects: 10
Study: 23157946

Group type: EXPERIMENTAL
Intervention: CTC gene signature expression in primary PDAC
Number of subjects: 6
Study: 23158458

Group type: EXPERIMENTAL
Intervention: Functional variants of HTR2A, including polymorphisms rs6311, rs76665058, and an unannotated SNP affecting mRNA expression and splicing.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Targeted analysis of HTR2A in the STAR*D study.
Number of subjects: 10
Study: 23159367

Group type: EXPERIMENTAL
Intervention: Siblings of patients with CRC
Number of subjects: 374

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 374
Study: 23160344

Group type: EXPERIMENTAL
Intervention: Pressure biofeedback test (maintaining pressure of 40 ± 5 mmHg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pressure biofeedback test
Number of subjects: 49
Study: 23160468

Group type: EXPERIMENTAL
Intervention: Low-dose donor lymphocyte infusions beginning 5 months after transplantation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: WT1-CTL responses before allogeneic transplantation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: WT1 expression in bone marrow
Number of subjects: 24